-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $23

Benzinga·12/08/2025 14:09:30
Listen to the news
Piper Sandler analyst Edward Tenthoff reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price target from $16 to $23.